Severe acute respiratory syndrome coronavirus 2 infection does not worsen the course of inflammatory bowel disease in the long term.
Eur J Gastroenterol Hepatol
; 35(9): 948-954, 2023 09 01.
Article
em En
| MEDLINE
| ID: mdl-37505974
ABSTRACT
BACKGROUND:
The long-term outcome of inflammatory bowel disease (IBD) patients after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is under investigation.AIM:
To assess, in a prospective study, whether a recent SARS-CoV-2 infection increases the risk of IBD relapse within 12â months.METHODS:
From March to April 2021, all IBD patients with recent (<2â months) SARS-CoV-2 infection (Cases) were enrolled. For each enrolled Case, four IBD Controls with no history of infection were considered. Clinical course of IBD was recorded for 12â months. Inclusion criteria well defined diagnosis of IBD; age ≥18 and ≤85â years; 12-month follow-up; consent. Exclusion criteria incomplete data; SARS-CoV-2 infection after enrollment. Additional inclusion criteria recent SARS-CoV-2 infection for Cases; no history of SARS-CoV-2 infection for Controls. Data expressed as median [range]. Statisticalanalysis:
Student-t-Test, Mann-Whitney U-test, χ2 test, multivariate logistic regression model [odds ratio (95% confidence interval)], Kaplan-Meier curves.RESULTS:
One hundred forty-three IBD patients were enrolled. The analysis included 118 patients (22 met the exclusion criteria, three lost at follow-up) 29 (24.6%) Cases and 89 (75.4%) Controls. Demographic and clinical characteristics were comparable between groups. During the 12-month study, the frequency of IBD relapse was comparable between Cases and Controls [8 (27%) vs 19 (21%); Pâ =â 0.65]. At univariate analysis, SARS-CoV-2 infection was not a risk factor for IBD relapse within 12â months [1.5 (0.6-3.9); Pâ =â 0.34]. At multivariate analysis, IBD activity at baseline was the only risk factor for relapse [3.2 (1.1-9.1); Pâ =â 0.03]. Kaplan-Meier curves showed that survival from IBD relapse was comparable between Cases and Controls (Pâ =â 0.33).CONCLUSION:
In a prospective 12-month study, a recent SARS-CoV-2 infection did not increase the risk of clinical relapse of IBD in the long term.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Inflamatórias Intestinais
/
COVID-19
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged80
/
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article